PT800399E - Tratamento terapeutico combinado de patologias hiperproliferativas - Google Patents

Tratamento terapeutico combinado de patologias hiperproliferativas

Info

Publication number
PT800399E
PT800399E PT96901387T PT96901387T PT800399E PT 800399 E PT800399 E PT 800399E PT 96901387 T PT96901387 T PT 96901387T PT 96901387 T PT96901387 T PT 96901387T PT 800399 E PT800399 E PT 800399E
Authority
PT
Portugal
Prior art keywords
therapeutic treatment
combined therapeutic
hyperproliferative pathologies
hyperproliferative
pathologies
Prior art date
Application number
PT96901387T
Other languages
English (en)
Inventor
Bruno Tocque
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of PT800399E publication Critical patent/PT800399E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/191Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
PT96901387T 1995-01-17 1996-01-12 Tratamento terapeutico combinado de patologias hiperproliferativas PT800399E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9500436A FR2729295A1 (fr) 1995-01-17 1995-01-17 Traitement therapeutique combine des pathologies hyperproliferatives

Publications (1)

Publication Number Publication Date
PT800399E true PT800399E (pt) 2002-12-31

Family

ID=9475169

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96901387T PT800399E (pt) 1995-01-17 1996-01-12 Tratamento terapeutico combinado de patologias hiperproliferativas

Country Status (21)

Country Link
US (3) US6262032B1 (pt)
EP (1) EP0800399B1 (pt)
JP (3) JP4580469B2 (pt)
KR (1) KR100385266B1 (pt)
AT (1) ATE222109T1 (pt)
AU (1) AU716364B2 (pt)
BR (1) BR9606969A (pt)
CA (1) CA2209771C (pt)
CZ (1) CZ298710B6 (pt)
DE (1) DE69622989T2 (pt)
DK (1) DK0800399T3 (pt)
ES (1) ES2180729T3 (pt)
FI (1) FI119911B (pt)
FR (1) FR2729295A1 (pt)
HU (1) HU229484B1 (pt)
MX (1) MX9704490A (pt)
NO (1) NO325418B1 (pt)
PT (1) PT800399E (pt)
SI (1) SI0800399T1 (pt)
SK (1) SK283989B6 (pt)
WO (1) WO1996022101A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044396A1 (en) * 1998-04-21 2003-03-06 Elia James P. Methods for treating diseases and increasing longevity
FR2729295A1 (fr) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
US7087582B1 (en) 1995-09-26 2006-08-08 Regents Of The University Of Michigan Combination for site-specifically transforming cells in vivo comprising a double-balloon catheter and nucleic acid comprising a gene encoding P21
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US20030064949A1 (en) * 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US20030060434A1 (en) * 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
AU2002236765A1 (en) * 2001-01-16 2002-07-30 Glaxo Group Limited Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
CA2530613A1 (en) * 2003-06-30 2005-01-06 Universite De Lausanne Rasgap derived peptide for selectively killing cancer cells
KR100809890B1 (ko) * 2003-12-24 2008-03-06 가부시키가이샤 로코모젠 암 억제 방법
JPWO2005061007A1 (ja) * 2003-12-24 2007-07-12 学校法人 聖マリアンナ医科大学 癌の抑制方法
GB0406415D0 (en) * 2004-03-22 2004-04-21 Inst Of Cancer Res The Materials and methods for treatment of cancer
US8124598B2 (en) 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
WO2008115478A2 (en) * 2007-03-19 2008-09-25 University Of Medicine And Dentistry Of New Jersey Method of cancer detection and treatment
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3751307T2 (de) * 1986-03-28 1995-09-21 Univ Illinois Zubereitungen und verfahren für klone, die, mit mehrfacharzneimittelresistenz assoziierte, dna-sequenzen in menschlichen zellen enthalten.
US6410010B1 (en) * 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
CA2136091A1 (en) * 1992-05-20 1993-11-25 Daniel S. Martin Chemotherapeutic drug combinations
DE69329336D1 (de) * 1992-05-28 2000-10-05 Xenova Ltd Acridin carboxamide zur behandlung von krebs
FR2694296B1 (fr) * 1992-07-30 1994-09-02 Rhone Poulenc Rorer Sa Peptides inhibant l'activité des protéines ras, préparation et utilisation.
AU676204B2 (en) * 1992-09-18 1997-03-06 Canji, Inc. Gene therapy by retroviral vector with tumor suppressive gene
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
TW442569B (en) 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
FR2729295A1 (fr) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6054467A (en) 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis

Also Published As

Publication number Publication date
FR2729295A1 (fr) 1996-07-19
CZ298710B6 (cs) 2008-01-02
FI973023A0 (fi) 1997-07-16
FI119911B (fi) 2009-05-15
JP2008133291A (ja) 2008-06-12
JP5031921B2 (ja) 2012-09-26
DK0800399T3 (da) 2002-12-02
AU716364B2 (en) 2000-02-24
JPH10512559A (ja) 1998-12-02
US20010021395A1 (en) 2001-09-13
EP0800399A1 (fr) 1997-10-15
EP0800399B1 (fr) 2002-08-14
SK95797A3 (en) 1997-12-10
SK283989B6 (sk) 2004-07-07
HUP9802423A3 (en) 2000-11-28
US6262032B1 (en) 2001-07-17
NO973197L (no) 1997-07-09
ATE222109T1 (de) 2002-08-15
ES2180729T3 (es) 2003-02-16
CA2209771C (fr) 2012-01-03
HU229484B1 (en) 2014-01-28
SI0800399T1 (en) 2002-12-31
KR100385266B1 (ko) 2005-09-07
US7884082B2 (en) 2011-02-08
NO973197D0 (no) 1997-07-09
JP2012036201A (ja) 2012-02-23
CZ226297A3 (en) 1997-10-15
FR2729295B1 (pt) 1997-02-28
DE69622989T2 (de) 2002-12-05
CA2209771A1 (fr) 1996-07-25
BR9606969A (pt) 1997-11-04
DE69622989D1 (de) 2002-09-19
US20050209177A9 (en) 2005-09-22
NO325418B1 (no) 2008-04-21
FI973023A (fi) 1997-07-16
WO1996022101A1 (fr) 1996-07-25
HUP9802423A2 (hu) 1999-02-01
US20040127437A1 (en) 2004-07-01
AU4542996A (en) 1996-08-07
KR19980701449A (ko) 1998-05-15
JP4580469B2 (ja) 2010-11-10
MX9704490A (es) 1997-10-31

Similar Documents

Publication Publication Date Title
PT800399E (pt) Tratamento terapeutico combinado de patologias hiperproliferativas
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
DE69600596D1 (de) Zweikammer-schrittmacher-anordnung zur kontinuierlichen regelung des av zeitintervalles mit dem ziel, optimierte stimulierung zur behandlung von kardiomyopathien zu erreichen
PT668763E (pt) Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento
PT998287E (pt) Utilizacao de levobupivacaina
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
PL340631A1 (en) Azelaic acid containing composition
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
ZA968905B (en) Transdermal therapeutic system (tts) for administering active substances for drug dependence or drug addiction
DE3687097T2 (de) Therapeutisches mittel zur behandlung haematopoietischer krankheiten.
PL336760A1 (en) Treatment of skin diseases
GB2331926A (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
IL118218A0 (en) Terpenoidic derivatives and pharmaceutical compositions containing them
MX9803610A (es) Utilizacion de flupirtina para la profilaxis y la terapia de enfermedades que van a compañadas de un deterioro del sistema celular hermatopoyetico.
IL116733A0 (en) The use of sertraline to treat cancer patients
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
ITRM960096V0 (it) Dispositivo per il trattamento del corpo umano.
NO984196L (no) FremgangsmÕte for behandling av stoffmisbruk
IL156144A0 (en) Novel therapeutic use of a thienylcyclohexylamine derivative
DE29501910U1 (de) Transdermales therapeutisches den Wirkstoff Dimethisoquin enthaltendes System
TR199801887A2 (xx) Bir Na+/H+ - de�i�tiricisi inhibit�r�.
DE69808839T2 (de) Makrophagen-stimulierende Protein für Behandlung von Erkrankungen des Nervensystems
GEP19991781B (en) Means for Treatment of Prostate Diseases
UA22223A (uk) Спосіб лікуваhhя захворюваhь оргаhа зору
ITBO950090A0 (it) Trattamento estetico di ricondizionamento dei tratti salienti del corpo umano